Hoth Therapeutics (NASDAQ: HOTH) files 8-K on new presentations to officials

Rhea-AI Filing Summary

Hoth Therapeutics, Inc. filed a Form 8-K to inform the market that it has prepared new presentation materials that management plans to use on and after January 16, 2026. These materials are intended for meetings with U.S. government officials focused on the company’s weight loss drug and broader therapeutics pipeline.

The presentation materials are provided as Exhibit 99.1. Hoth notes that the information in these materials is summary in nature and should be read together with its other SEC filings and public announcements. The company states that the materials speak as of the date of this Form 8-K and, while it may update them in the future, it specifically disclaims any obligation to do so.

false 0001711786 0001711786 2026-01-16 2026-01-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 16, 2026

Hoth Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-38803		82-1553794
(State or other jurisdiction of incorporation)		(Commission File Number)		(I. R. S. Employer Identification No.)

1177 Avenue of the Americas, 5th Floor, Suite 5066

New York, NY 10036

(Address of principal executive offices, including ZIP code)

(646) 756-2997

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value		HOTH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Hoth Therapeutics, Inc. (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time on and after January 16, 2026, for meetings with US government officials for its weight loss drug and its therapeutics pipeline. The Presentation Materials are filed as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in the Presentation Materials is summary information that should be considered within the context of the Company’s filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While the Company may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any obligation to do so.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Presentation Materials
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 16, 2026	Hoth Therapeutics, Inc.
	/s/ Robb Knie
	Robb Knie
	Chief Executive Officer

2

FAQ

What is Hoth Therapeutics (HOTH) reporting in this Form 8-K?

Hoth Therapeutics is reporting that it has prepared new presentation materials that management plans to use in meetings with U.S. government officials about its weight loss drug and therapeutics pipeline.

Who is the intended audience for Hoth Therapeutics' new presentation materials?

The presentation materials are intended for meetings with U.S. government officials, focusing on Hoth Therapeutics' weight loss drug and its broader therapeutics pipeline.

Where can investors find the presentation materials mentioned by Hoth Therapeutics?

The presentation materials are filed as Exhibit 99.1 to the Form 8-K, and can be accessed alongside the company’s other SEC filings.

Does this Hoth Therapeutics Form 8-K include new financial results?

No financial results are described in this report. It focuses on the availability of presentation materials for meetings with U.S. government officials.

From what date does Hoth plan to use these presentation materials?

Hoth Therapeutics states that management intends to use the presentation materials from time to time on and after January 16, 2026.

Does Hoth Therapeutics commit to updating the presentation materials in the future?

Hoth Therapeutics notes it may update the presentation materials but specifically disclaims any obligation to do so, and states that the materials speak as of the date of the Form 8-K.